-
The Applications of 2,4'-bipyriMidin-2'-aMine
Time of Update: 2023-05-05
Its ability to coordinate with metal ions and atoms makes it a versatile and useful reagent in the production of catalysts, metalloproteins, metalloenzymes, antimicrobial and antifungal agents, pigments, dyes, and other materials.
-
Chiropractic Rejuvenation and Concerted Efforts Review of the 1st Adult Spinal Muscular Atrophy Summit Forum
Time of Update: 2023-01-06
Professor Zhang Min: Real-world studies enrich the evidence for the treatment of SMA in adults, and DMT drugs bring significant benefitsProfessor Zhang Min, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology➤ Several pivotal studies confirm the efficacy and safety of nocinaxen in children and adultsMultiple natural history studies have found progressive decline in functions in patients with SMA.
-
Chiropractic Rejuvenation and Concerted Efforts Review of the 1st Adult Spinal Muscular Atrophy Summit Forum
Time of Update: 2023-01-06
Professor Zhang Min: Real-world studies enrich the evidence for the treatment of SMA in adults, and DMT drugs bring significant benefitsProfessor Zhang Min, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology➤ Several pivotal studies confirm the efficacy and safety of nocinaxen in children and adultsMultiple natural history studies have found progressive decline in functions in patients with SMA.
-
BeiGene released the latest data at the 2022 European Conference on Oncology, including the results of an oral report on the study of terelizumab for first-line unresectable hepatocellular carcinoma
Time of Update: 2022-09-21
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
Blood: Effects of FLT3 inhibitor Gilteritinib vs salvage chemotherapy on long-term outcomes in patients with relapsed/refractory AML
Time of Update: 2022-04-22
Chemotherapy combination) significantly improved the survival rate and remission rate of AML patientsThe randomized phase 3 ADMIRAL trial compared gilteritinib with salvage chemotherapy in patients with FLT3 mutation-positive (+) relapsed or refractory AML .
-
National Medical Insurance Bureau: On average, 116 drugs per province will be reduced in price, affecting all pharmacies
Time of Update: 2022-03-07
In December 2021, the person in charge of the Henan Medical Insurance Bureau clearly stated that this spring, the province will launch a pilot program of "the first batch of pharmacies to sell centralized medicines" .
-
Technical Guidelines for Clinical Trials of New Antiviral Drugs for Novel Coronavirus Pneumonia (Trial) Released
Time of Update: 2022-03-05
Provide general technical guidance and reference for clinical trial design, implementation and evaluation of antiviral drugs for novel coronavirus pneumonia .
-
The National Medical Insurance Administration determines the rules for renewing contracts with volume purchases
Time of Update: 2021-11-14
All provinces, autonomous regions, municipalities directly under the Central Government, and Xinjiang Production and Construction Corps Medical Insurance Bureau: To implement the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Mass Procurement of Drugs" (Guobanfa [2021] No.
-
Where is the "god" effect of the hypoglycemic drug metformin on rheumatism
Time of Update: 2021-10-22
1. Rheumatoid arthritis (RA): Metformin can affect the neutrophil extracellular bactericidal network (NETs), M2 type macrophages, The expression of rheumatoid factor (RF) subgroups can simultaneously play a role in bone protection and regulate the effects of intestinal microbes to achieve RA remission, which may open up a new clinical treatment perspective for RA; and has the advantages of fewer adverse reactions and low cost, which is expected Become one of the more ideal treatment drugs for RA .
-
Huiyu Pharmaceuticals has another new product to attack this year's fifth injection reported
Time of Update: 2021-01-11
left ethyl laxitan injection with thick solution in the domestic market late, has not yet formed a large-scale sales, in 2019 accounted for 2.1% of the overall market share of left ethyl lysidan, in 2020 H1 rose to 4.2%.
source: MiNet database, CDE official website
-
Today's Healthy Bell Listing: Leading the Last Wave of Retail Pharmacies
Time of Update: 2020-12-13
Chart 1: Number of stores per company for 2017-2019 Source: Prospects, China Kang Industrial Capital Research Center in terms of company revenue, Healthy and Shuyu civilian size is comparable, and Jianjia compared to The latter maintained a relatively good growth momentum, with year-on-year growth rates of 14.27 per cent, 17.85 per cent and 27.56 per cent year-on-year in 2017-2019, respectively, with relatively small revenues.
-
Diagnosis and treatment of GBM soft meninges
Time of Update: 2020-11-09
The results showed that GBM cells migrated from the initial position of the tumor along the soft membrane of cerebrovascular vessels, under the cobweb membrane and under the chamber membrane (Figure 1).
-
J Immuno Cancer: A Comparative Analysis of Phase III Clinical Trials for The Treatment of Head and Neck Squamous Cell Carcinoma Patients with Anti-PD1 Single Drug
Time of Update: 2020-07-13
Two Phase III clinical trials (CheckMate 141 and KEYNOTE 040) have independently demonstrated that the total lifetime (OS) of patients with failed platinum-based treatment can be improved with anti-
-
First-line late non-scaly NSCLC! Application for listing of reilly Pearl monoanti-new indication was accepted
Time of Update: 2020-07-11
The sNDA for non-scale NSCLC is based on the results of a Phase 3 clinical trial, which is Bacaan ® combined with permeitus and the platinum chemotherapy drug (carped or cisplatin) chosen by the resea
-
Clinical trial of YPS345, a class 1 innovative drug, was approved by the State Drug Administration
Time of Update: 2020-06-10
Today, china Pharmaceutical (http:// issued a notice that its wholly-owned subsidiary (http:// Tianfang Pharmaceutical Co., Ltd received a notice of acceptance of the clinical test (http://
